Which has stronger valuation & earnings, MEDP or CHE?

Medpace has higher revenue and earnings than Chemed. Chemed is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 6.01 $451.12M $15.91 33.46 Chemed $2.53B 2.71 $265.24M $18.35 28.11

Is MEDP or CHE more profitable?

Medpace has a net margin of 17.19% compared to Chemed's net margin of 10.23%. Medpace's return on equity of 120.89% beat Chemed's return on equity. Company Net Margins Return on Equity Return on Assets Medpace 17.19% 120.89% 24.79% Chemed 10.23% 27.18% 17.38%

Does the media favor MEDP or CHE?

In the previous week, Medpace had 1 more articles in the media than Chemed. MarketBeat recorded 7 mentions for Medpace and 6 mentions for Chemed. Chemed's average media sentiment score of 1.38 beat Medpace's score of 1.24 indicating that Chemed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Chemed 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, DGX or CHE?

Quest Diagnostics has higher revenue and earnings than Chemed. Quest Diagnostics is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quest Diagnostics $11.04B 2.08 $992M $9.05 22.91 Chemed $2.53B 2.71 $265.24M $18.35 28.11

Is DGX or CHE more profitable?

Chemed has a net margin of 10.23% compared to Quest Diagnostics' net margin of 9.07%. Chemed's return on equity of 27.18% beat Quest Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Quest Diagnostics 9.07% 15.60% 7.06% Chemed 10.23% 27.18% 17.38%

Does the media refer more to DGX or CHE?

In the previous week, Quest Diagnostics had 7 more articles in the media than Chemed. MarketBeat recorded 13 mentions for Quest Diagnostics and 6 mentions for Chemed. Chemed's average media sentiment score of 1.38 beat Quest Diagnostics' score of 0.97 indicating that Chemed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quest Diagnostics 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Chemed 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, CHE or LH?

Labcorp has higher revenue and earnings than Chemed. Labcorp is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemed $2.53B 2.71 $265.24M $18.35 28.11 Labcorp $13.95B 1.64 $876.50M $11.29 24.76

Is CHE or LH more profitable?

Chemed has a net margin of 10.23% compared to Labcorp's net margin of 6.66%. Chemed's return on equity of 27.18% beat Labcorp's return on equity. Company Net Margins Return on Equity Return on Assets Chemed 10.23% 27.18% 17.38% Labcorp 6.66% 16.29% 7.62%

Does the media refer more to CHE or LH?

In the previous week, Labcorp had 4 more articles in the media than Chemed. MarketBeat recorded 10 mentions for Labcorp and 6 mentions for Chemed. Chemed's average media sentiment score of 1.38 beat Labcorp's score of 1.32 indicating that Chemed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Chemed 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Labcorp 10 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, DVA or CHE?

DaVita has higher revenue and earnings than Chemed. DaVita is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DaVita $13.64B 1.11 $746.80M $10.78 21.92 Chemed $2.53B 2.71 $265.24M $18.35 28.11

Is DVA or CHE more profitable?

Chemed has a net margin of 10.23% compared to DaVita's net margin of 5.65%. Chemed's return on equity of 27.18% beat DaVita's return on equity. Company Net Margins Return on Equity Return on Assets DaVita 5.65% -270.37% 4.87% Chemed 10.23% 27.18% 17.38%

Does the media prefer DVA or CHE?

In the previous week, DaVita had 1 more articles in the media than Chemed. MarketBeat recorded 7 mentions for DaVita and 6 mentions for Chemed. Chemed's average media sentiment score of 1.38 beat DaVita's score of 0.61 indicating that Chemed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DaVita 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Chemed 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer CHE or CRVL?

Chemed presently has a consensus price target of $480.25, suggesting a potential downside of 6.91%. Given Chemed's stronger consensus rating and higher probable upside, equities analysts plainly believe Chemed is more favorable than CorVel. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chemed 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17 CorVel 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, CHE or CRVL?

Chemed has higher revenue and earnings than CorVel. Chemed is trading at a lower price-to-earnings ratio than CorVel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemed $2.53B 2.71 $265.24M $18.35 28.11 CorVel $958.53M 3.27 $110.34M $2.14 28.74

Is CHE or CRVL more profitable?

CorVel has a net margin of 11.51% compared to Chemed's net margin of 10.23%. CorVel's return on equity of 29.92% beat Chemed's return on equity. Company Net Margins Return on Equity Return on Assets Chemed 10.23% 27.18% 17.38% CorVel 11.51% 29.92% 17.68%

Does the media refer more to CHE or CRVL?

In the previous week, Chemed had 4 more articles in the media than CorVel. MarketBeat recorded 6 mentions for Chemed and 2 mentions for CorVel. Chemed's average media sentiment score of 1.38 beat CorVel's score of 0.89 indicating that Chemed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Chemed 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CorVel 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Chemed (CHE) Competitors

$514.18 +4.16 (+0.81%)

As of 03:53 PM Eastern

Compare

CHE vs. MEDP, DGX, LH, DVA, and CRVL

Should you buy Chemed stock or one of its competitors? MarketBeat compares Chemed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Chemed include Medpace (MEDP), Quest Diagnostics (DGX), Labcorp (LH), DaVita (DVA), and CorVel (CRVL).

How does Chemed compare to Medpace?

Medpace (NASDAQ:MEDP) and Chemed (NYSE:CHE) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Medpace presently has a consensus price target of $469.50, suggesting a potential downside of 11.80%. Chemed has a consensus price target of $480.25, suggesting a potential downside of 6.91%. Given Chemed's stronger consensus rating and higher possible upside, analysts plainly believe Chemed is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	1 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.07
Chemed	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

Medpace has a net margin of 17.19% compared to Chemed's net margin of 10.23%. Medpace's return on equity of 120.89% beat Chemed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.19%	120.89%	24.79%
Chemed	10.23%	27.18%	17.38%

In the previous week, Medpace had 1 more articles in the media than Chemed. MarketBeat recorded 7 mentions for Medpace and 6 mentions for Chemed. Chemed's average media sentiment score of 1.38 beat Medpace's score of 1.24 indicating that Chemed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Chemed	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Medpace has higher revenue and earnings than Chemed. Chemed is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	6.01	$451.12M	$15.91	33.46
Chemed	$2.53B	2.71	$265.24M	$18.35	28.11

78.0% of Medpace shares are held by institutional investors. Comparatively, 95.9% of Chemed shares are held by institutional investors. 20.5% of Medpace shares are held by insiders. Comparatively, 3.3% of Chemed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Medpace has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, Chemed has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market.

Summary

Medpace beats Chemed on 11 of the 16 factors compared between the two stocks.

How does Chemed compare to Quest Diagnostics?

Quest Diagnostics (NYSE:DGX) and Chemed (NYSE:CHE) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

In the previous week, Quest Diagnostics had 7 more articles in the media than Chemed. MarketBeat recorded 13 mentions for Quest Diagnostics and 6 mentions for Chemed. Chemed's average media sentiment score of 1.38 beat Quest Diagnostics' score of 0.97 indicating that Chemed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quest Diagnostics	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Chemed	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quest Diagnostics currently has a consensus price target of $217.17, suggesting a potential upside of 4.75%. Chemed has a consensus price target of $480.25, suggesting a potential downside of 6.91%. Given Quest Diagnostics' stronger consensus rating and higher possible upside, analysts clearly believe Quest Diagnostics is more favorable than Chemed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Chemed	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

Chemed has a net margin of 10.23% compared to Quest Diagnostics' net margin of 9.07%. Chemed's return on equity of 27.18% beat Quest Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quest Diagnostics	9.07%	15.60%	7.06%
Chemed	10.23%	27.18%	17.38%

88.1% of Quest Diagnostics shares are held by institutional investors. Comparatively, 95.9% of Chemed shares are held by institutional investors. 0.9% of Quest Diagnostics shares are held by company insiders. Comparatively, 3.3% of Chemed shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Quest Diagnostics pays an annual dividend of $3.44 per share and has a dividend yield of 1.7%. Chemed pays an annual dividend of $2.40 per share and has a dividend yield of 0.5%. Quest Diagnostics pays out 38.0% of its earnings in the form of a dividend. Chemed pays out 13.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Quest Diagnostics has increased its dividend for 14 consecutive years and Chemed has increased its dividend for 16 consecutive years.

Quest Diagnostics has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market. Comparatively, Chemed has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

Quest Diagnostics has higher revenue and earnings than Chemed. Quest Diagnostics is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quest Diagnostics	$11.04B	2.08	$992M	$9.05	22.91
Chemed	$2.53B	2.71	$265.24M	$18.35	28.11

Summary

Chemed beats Quest Diagnostics on 11 of the 19 factors compared between the two stocks.

How does Chemed compare to Labcorp?

Chemed (NYSE:CHE) and Labcorp (NYSE:LH) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

Labcorp has higher revenue and earnings than Chemed. Labcorp is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemed	$2.53B	2.71	$265.24M	$18.35	28.11
Labcorp	$13.95B	1.64	$876.50M	$11.29	24.76

Chemed presently has a consensus price target of $480.25, indicating a potential downside of 6.91%. Labcorp has a consensus price target of $314.40, indicating a potential upside of 12.48%. Given Labcorp's stronger consensus rating and higher probable upside, analysts plainly believe Labcorp is more favorable than Chemed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemed	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
Labcorp	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.82

Chemed has a net margin of 10.23% compared to Labcorp's net margin of 6.66%. Chemed's return on equity of 27.18% beat Labcorp's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemed	10.23%	27.18%	17.38%
Labcorp	6.66%	16.29%	7.62%

Chemed has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, Labcorp has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market.

95.9% of Chemed shares are held by institutional investors. Comparatively, 95.9% of Labcorp shares are held by institutional investors. 3.3% of Chemed shares are held by company insiders. Comparatively, 0.8% of Labcorp shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Chemed pays an annual dividend of $2.40 per share and has a dividend yield of 0.5%. Labcorp pays an annual dividend of $2.88 per share and has a dividend yield of 1.0%. Chemed pays out 13.1% of its earnings in the form of a dividend. Labcorp pays out 25.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Chemed has increased its dividend for 16 consecutive years.

In the previous week, Labcorp had 4 more articles in the media than Chemed. MarketBeat recorded 10 mentions for Labcorp and 6 mentions for Chemed. Chemed's average media sentiment score of 1.38 beat Labcorp's score of 1.32 indicating that Chemed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Chemed	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Labcorp	10 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Chemed beats Labcorp on 10 of the 19 factors compared between the two stocks.

How does Chemed compare to DaVita?

DaVita (NYSE:DVA) and Chemed (NYSE:CHE) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Chemed has a net margin of 10.23% compared to DaVita's net margin of 5.65%. Chemed's return on equity of 27.18% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DaVita	5.65%	-270.37%	4.87%
Chemed	10.23%	27.18%	17.38%

DaVita presently has a consensus target price of $216.50, indicating a potential downside of 8.38%. Chemed has a consensus target price of $480.25, indicating a potential downside of 6.91%. Given Chemed's stronger consensus rating and higher possible upside, analysts plainly believe Chemed is more favorable than DaVita.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DaVita	1 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.13
Chemed	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

In the previous week, DaVita had 1 more articles in the media than Chemed. MarketBeat recorded 7 mentions for DaVita and 6 mentions for Chemed. Chemed's average media sentiment score of 1.38 beat DaVita's score of 0.61 indicating that Chemed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DaVita	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Chemed	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

90.1% of DaVita shares are owned by institutional investors. Comparatively, 95.9% of Chemed shares are owned by institutional investors. 1.9% of DaVita shares are owned by company insiders. Comparatively, 3.3% of Chemed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

DaVita has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, Chemed has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market.

DaVita has higher revenue and earnings than Chemed. DaVita is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DaVita	$13.64B	1.11	$746.80M	$10.78	21.92
Chemed	$2.53B	2.71	$265.24M	$18.35	28.11

Summary

Chemed beats DaVita on 11 of the 16 factors compared between the two stocks.

How does Chemed compare to CorVel?

Chemed (NYSE:CHE) and CorVel (NASDAQ:CRVL) are both mid-cap health care services companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Chemed has higher revenue and earnings than CorVel. Chemed is trading at a lower price-to-earnings ratio than CorVel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemed	$2.53B	2.71	$265.24M	$18.35	28.11
CorVel	$958.53M	3.27	$110.34M	$2.14	28.74

95.9% of Chemed shares are owned by institutional investors. Comparatively, 51.4% of CorVel shares are owned by institutional investors. 3.3% of Chemed shares are owned by company insiders. Comparatively, 39.7% of CorVel shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

CorVel has a net margin of 11.51% compared to Chemed's net margin of 10.23%. CorVel's return on equity of 29.92% beat Chemed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemed	10.23%	27.18%	17.38%
CorVel	11.51%	29.92%	17.68%

Chemed presently has a consensus price target of $480.25, suggesting a potential downside of 6.91%. Given Chemed's stronger consensus rating and higher probable upside, equities analysts plainly believe Chemed is more favorable than CorVel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemed	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
CorVel	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Chemed has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market. Comparatively, CorVel has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market.

In the previous week, Chemed had 4 more articles in the media than CorVel. MarketBeat recorded 6 mentions for Chemed and 2 mentions for CorVel. Chemed's average media sentiment score of 1.38 beat CorVel's score of 0.89 indicating that Chemed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Chemed	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CorVel	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Chemed beats CorVel on 9 of the 16 factors compared between the two stocks.

Get Chemed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CHE vs. The Competition

Export

Metric	Chemed	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$6.85B	$6.39B	$6.81B	$23.30B
Dividend Yield	0.47%	1.39%	2.67%	4.16%
P/E Ratio	28.11	42.10	27.16	30.78
Price / Sales	2.71	39.70	573.91	21.03
Price / Cash	20.68	19.72	29.05	18.80
Price / Book	7.46	3.96	10.68	4.75
Net Income	$265.24M	$218.81M	$3.59B	$1.06B
7 Day Performance	4.63%	4.04%	-1.50%	-0.04%
1 Month Performance	18.09%	16.68%	1.17%	0.90%
1 Year Performance	14.40%	43.70%	24.50%	16.63%

Chemed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CHE Chemed	3.9866 of 5 stars	$514.19 +0.8%	$480.25 -6.6%	+13.1%	$6.82B	$2.53B	28.02	15,811	News Coverage Positive News Analyst Upgrade
MEDP Medpace	2.0811 of 5 stars	$530.19 -1.5%	$469.50 -11.4%	+72.4%	$15.37B	$2.53B	33.32	6,200	Upcoming Earnings
DGX Quest Diagnostics	4.3651 of 5 stars	$207.29 -0.1%	$217.17 +4.8%	+26.4%	$22.96B	$11.04B	22.91	57,000	Upcoming Earnings Analyst Downgrade
LH Labcorp	4.7605 of 5 stars	$276.46 -0.1%	$314.40 +13.7%	+16.4%	$22.70B	$13.95B	24.49	71,000	Positive News
DVA DaVita	3.6162 of 5 stars	$235.52 +1.2%	$209.00 -11.3%	+67.9%	$14.95B	$13.64B	21.85	78,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CHE) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Chemed (CHE) Competitors